At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,459 enrolled
Drug / intervention
Tofacitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ESCALATE-RA A NON-INTERVENTIONAL STUDY OF CRITICAL FACTORS FOR ESCALATING DRUG TREATMENT IN PATIENTS TREATED WITH TOFACITINIB FOR MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS
In Brief
An observational study evaluating Tofacitinib for Arthritis, Rheumatoid. Completed, enrolled 1,459 participants across 91 sites.
Detailed Summary
This non-interventional study aims to identify key factors that are driving treatment decisions by rheumatologists in the treatment of rheumatoid arthritis (RA) patients starting treatment with Tofacitinib in a real world setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedJan 2018
Primary CompletionJul 2023
TodayJul 2026
First PostedJan 2, 2018
Enrollment StartNov 2, 2017
Primary CompletionJul 17, 2023
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.5 years ago
Interventions
Tofacitinibdrug
Patients who are started on Tofacitinib treatment according to the drug label